129 related articles for article (PubMed ID: 8234324)
1. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat.
Wilson DK; Tarle I; Petrash JM; Quiocho FA
Proc Natl Acad Sci U S A; 1993 Nov; 90(21):9847-51. PubMed ID: 8234324
[TBL] [Abstract][Full Text] [Related]
2. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
3. Structural studies of aldo-keto reductase inhibition.
Wilson DK; Nakano T; Petrash JM; Quiocho FA
Adv Exp Med Biol; 1997; 414():435-42. PubMed ID: 9059648
[No Abstract] [Full Text] [Related]
4. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants.
Singh SB; Malamas MS; Hohman TC; Nilakantan R; Carper DA; Kitchen D
J Med Chem; 2000 Mar; 43(6):1062-70. PubMed ID: 10737739
[TBL] [Abstract][Full Text] [Related]
6. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
Mylari BL; Larson ER; Beyer TA; Zembrowski WJ; Aldinger CE; Dee MF; Siegel TW; Singleton DH
J Med Chem; 1991 Jan; 34(1):108-22. PubMed ID: 1899452
[TBL] [Abstract][Full Text] [Related]
7. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of human aldehyde reductase: characterization of the active site pocket.
Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
[TBL] [Abstract][Full Text] [Related]
9. The structure of human recombinant aldose reductase complexed with the potent inhibitor zenarestat.
Kinoshita T; Miyake H; Fujii T; Takakura S; Goto T
Acta Crystallogr D Biol Crystallogr; 2002 Apr; 58(Pt 4):622-6. PubMed ID: 11914486
[TBL] [Abstract][Full Text] [Related]
10. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications.
Wilson DK; Bohren KM; Gabbay KH; Quiocho FA
Science; 1992 Jul; 257(5066):81-4. PubMed ID: 1621098
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
[TBL] [Abstract][Full Text] [Related]
12. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
[TBL] [Abstract][Full Text] [Related]
13. Structure of porcine aldehyde reductase holoenzyme.
el-Kabbani O; Judge K; Ginell SL; Myles DA; DeLucas LJ; Flynn TG
Nat Struct Biol; 1995 Aug; 2(8):687-92. PubMed ID: 7552731
[TBL] [Abstract][Full Text] [Related]
14. Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductase.
Koch C; Heine A; Klebe G
Biochim Biophys Acta; 2011 Sep; 1810(9):879-87. PubMed ID: 21684320
[TBL] [Abstract][Full Text] [Related]
15. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D
Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881
[TBL] [Abstract][Full Text] [Related]
16. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
El-Kabbani O; Old SE; Ginell SL; Carper DA
Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
[TBL] [Abstract][Full Text] [Related]
17. The crystal structure of the aldose reductase.NADPH binary complex.
Borhani DW; Harter TM; Petrash JM
J Biol Chem; 1992 Dec; 267(34):24841-7. PubMed ID: 1447221
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of CHO reductase, a member of the aldo-keto reductase superfamily.
Ye Q; Hyndman D; Li X; Flynn TG; Jia Z
Proteins; 2000 Jan; 38(1):41-8. PubMed ID: 10651037
[TBL] [Abstract][Full Text] [Related]
19. 1.7 A structure of FR-1, a fibroblast growth factor-induced member of the aldo-keto reductase family, complexed with coenzyme and inhibitor.
Wilson DK; Nakano T; Petrash JM; Quiocho FA
Biochemistry; 1995 Nov; 34(44):14323-30. PubMed ID: 7578036
[TBL] [Abstract][Full Text] [Related]
20. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
